Payment overview · 2025
General Payments
$1,970.04
72 reported records · 22 companies
Healthcare provider profile · identity verified
Gary Dicanio, DO
Allopathic & Osteopathic Physicians|Family Medicine · PATCHOGUE, NY · NPI 1770665721
Verified facts
What the public records show
CMS Open Payments records show Gary Dicanio, DO received $1,970.04 in general payments during 2025 across 72 reported records.
ABBVIE INC. accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nurtec Odt, Ozempic, Roxybond, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PROTEGA PHARMACEUTIALS INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ROXYBOND as an associated drug or biological on 2633 records involving 1078 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Roxybond by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $339.15 | 17.2% | 18 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $273.29 | 13.9% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $220.38 | 11.2% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $171.58 | 8.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $159.76 | 8.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $141.28 | 7.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $104.17 | 5.3% | 5 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $102.12 | 5.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.61 | 4.4% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $64.05 | 3.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.52 | 2.6% | 2 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $46.27 | 2.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.72 | 1.5% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $26.16 | 1.3% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.70 | 1.2% | 1 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $21.71 | 1.1% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $20.34 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.84 | 1.0% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $19.73 | 1.0% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $19.33 | 1.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.38 | 0.8% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $13.95 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,970.04 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $273.29 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $231.82 | 13 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $220.38 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $209.32 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $171.58 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $139.71 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $126.63 | 2 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $102.12 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $89.21 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $86.61 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $86.61 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $83.78 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.82 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $50.52 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.27 | 2 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $46.27 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $44.51 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.94 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.72 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.37 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.15 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ROXYBOND roxybond |
2025 | Roxybond | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PROTEGA PHARMACEUTIALS INC Exact reporting entity; no affiliate inference |
2025 | ROXYBOND open payments reported associated product |
CMS Open Payments — General Payments 2633 supporting records · 1078 recipient NPIs · example record 1235986235 |
Roxybond · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 178 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 146 | 35 |
| Alprazolam | Alprazolam | 133 | 19 |
| Omeprazole | Omeprazole | 111 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 13 |
| Losartan Potassium | Losartan Potassium | 79 | 22 |
| Sodium Chloride | 0.9 % Sodium Chloride | 78 | suppressed |
| Famotidine | Famotidine | 75 | 20 |
| Gabapentin | Gabapentin | 71 | 20 |
| Metformin Hcl | Metformin Hcl | 70 | 33 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 67 | suppressed |
| Lisinopril | Lisinopril | 65 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 63 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 62 | 16 |
| Montelukast Sodium | Montelukast Sodium | 61 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 16 |
| Alendronate Sodium | Alendronate Sodium | 58 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 51 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 16 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Eliquis | Apixaban | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 33 | suppressed |
| Naproxen | Naproxen | 33 | 15 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Levetiracetam-Nacl | Levetiracetam In Nacl (Iso-Os) | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Furosemide | Furosemide | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Roxybond | Oxycodone Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Ramipril | Ramipril | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Nucynta | Tapentadol Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,970.04 · 72 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, APLENZIN, BRIXADI, COMIRNATY, CREON, Cologuard Collection Kit, DUPIXENT, ELIQUIS, Flexitouch Plus, GEMTESA, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, LINZESS, MOUNJARO, MOVANTIK, NALOCET, NURTEC ODT, Nimbl, OTEZLA, Ozempic, PREVNAR 20, PROLATE, QULIPTA, REPATHA, REXULTI, ROXYBOND, Rybelsus, Sunosi, TANLOR, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND, ZTLido | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error